Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: An evaluation of seven common cancers

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2157-2162

  Park, Ju Hyun ^a   Gail, Mitchell H ^a   Greene, Mark H ^a   Chatterjee, Nilanjan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COLORECTAL CANCER; EFFECT SIZE; FALSE POSITIVE RESULT; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GLIOMA; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; MALE; OVARY CANCER; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; EARLY DETECTION OF CANCER; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK; RISK FACTORS;

EID: 84863975398     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1943     Document Type: Article

References (35)

1. Costantino JP, Gail MH, Pee D, et al: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548, 1999 (Pubitemid 29457958)
2. Rockhill B, Spiegelman D, Byrne C, et al: Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358-366, 2001 (Pubitemid 32229380)
3. Gail MH, Pfeiffer RM: On criteria for evaluating models of absolute risk. Biostatistics 6:227-239, 2005 (Pubitemid 41240355)
4. Gail MH: Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 30:1090-1104, 2011
5. Pfeiffer RM, Gail MH: Two criteria for evaluating risk prediction models. Biometrics 2010:1541-0420, 2010
6. Pharoah PD, Antoniou A, Bobrow M, et al: Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33-36, 2002
7. van Zitteren M van der Net JB, Kundu S, et al: Genome-based prediction of breast cancer risk in the general population: A modeling study based on meta-analyses of genetic associations. Cancer Epidemiol Biomarkers Prev 20:9-22, 2011
8. Gail MH: Discriminatory accuracy from singlenucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100:1037-1041, 2008
9. Johansson M, Holmström B, Hinchliffe SR, et al: Combining 33 genetic variants with prostatespecific antigen for prediction of prostate cancer: Longitudinal study. Int J Cancer 130:129-137, 2012
10. Pashayan N, Duffy SW, Chowdhury S, et al: Polygenic susceptibility to prostate and breast cancer: Implications for personalised screening. Br J Cancer 104:1656-1663, 2011
11. Pharoah PD, Antoniou AC, Easton DF, et al: Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358:2796-2803, 2008 (Pubitemid 351930854)
12. Salinas CA, Koopmeiners JS, Kwon EM, et al: Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 69:363-372, 2009
13. Wacholder S, Hartge P, Prentice R, et al: Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362:986-993, 2010
14. Zheng SL, Sun J, Wiklund F, et al: Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358:910-919, 2008 (Pubitemid 351397090)
15. Park JH, Wacholder S, Gail MH, et al: Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 42:570-575, 2010
16. Ghosh A, Zou F, Wright FA: Estimating odds ratios in genome scans: An approximate conditional likelihood approach. Am J Hum Genet 82:1064-1074, 2008
17. Pepe MS: The Statistical Evaluation of Medical Tests for Classification and Prediction. New York, NY, Oxford University Press, 2003
18. Weissfeld JL, Schoen RE, Pinsky PF, et al: Flexible sigmoidoscopy in the PLCO cancer screening trial: Results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 97:989-997, 2005
19. Buys SS, Partridge E, Greene MH, et al: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193:1630-1639, 2005 (Pubitemid 41540458)
20. Gail MH: Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 101:959-963, 2009
21. Freedman AN, Slattery ML, Ballard-Barbash R, et al: Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 27:686-693, 2009
22. Wu X, Lin J, Grossman HB, et al: Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 25:4974-4981, 2007 (Pubitemid 350220430)
23. Stadler ZK, Thom P, Robson ME, et al: Genome-wide association studies of cancer. J Clin Oncol 28:4255-4267
24. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002 (Pubitemid 34260526)
25. Lango Allen H, Estrada K, Lettre G, et al: Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467:832-838, 2010
26. Teslovich TM, Musunuru K, Smith AV, et al: Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466:707-713, 2010
27. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostatecancer screening trial. N Engl J Med 360:1310-1319, 2009
28. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised populationbased prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
29. Baker SG, Cook NR, Vickers A, et al: Using relative utility curves to evaluate risk prediction. JR Stat Soc Ser A Stat Soc 172:729-748, 2009
30. Pauker SG, Kassirer JP: Therapeutic decisionmaking: Cost-benefit analysis. N Engl J Med 293:229-234, 1975
31. Vickers AJ, Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 26:565-574, 2006 (Pubitemid 44728772)
32. Ciampa J, Yeager M, Amundadottir L, et al: Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genomewide association study. Cancer Res 71:3287-3295, 2011
33. Allen HL, Estrada K, Lettre G, et al: Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467:832-838
34. Purcell SM, Wray NR, Stone JL, et al: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752, 2009
35. Chatterjee N, Park JH, Caporaso N, et al: Predicting the future of genetic risk prediction. Cancer Epidemiol Biomarkers Prev 20:3-8, 2011